NIPC Law

Darlington Memorial Hospital Steven Fruitsmaak / CC BY (https://creativecommons.org/licenses/by/3.0) Jane Lambert Court of Appeal (Lords Justice Underhill and Floyd and Lady Justice Rose) Bayer Plc and Another v NHS Darlington Clinical Commissioning Group and others   [2020] EWCA Civ 449 (25 March 2020) This was an appeal by Bayer Plc and Novartis Pharmaceuticals UK Limited against Mrs Justice Whipple's judgment in Bayer Plc v NHS Darlington Clinical Commissioning Groups and others   :  [2019] PTSR 922, [2018] WLR(D) 589, [2018] EWHC 2465 (Admin) which I blogged in  Bayer Plc v NHS Darlington CCG and Others   2 Oct 2018. In her judgment, Mrs Justice Whipple dismissed applications for judicial review by Bayer and Novartis of a decision by NHS Darlington and other Clinical Commissioning Groups in Northeast England that the NHS Trusts from which they commission services should use a drug called Avastin as the preferred treatment option f...

Back of an eye showing age-related macular degeneration Author US National Eye Institute Source Wikipedia Jane Lambert Administrative Court (Mrs Justice Whipple)  Bayer Plc v NHS Darlington CCG and other s    [2018] EWHC 2465 (Admin) 21 Sept 2018 This case was an application by Bayer Plc  and Novartis Pharmaceuticals UK Ltd . for judicial review of a decision by 12  clinical commissioning groups   ( "CCGs" )   in Northeast England to offer patients with wet AMD   ( age-r elated macular degeneration) injections of a drug known as Avastin or bevacizumab. The reason for their decision is that Avastin costs £28 per injection compared to £816 for Bayer's EYLEA  and £551 for Novartis's Lucentis .  The CCGs had made their decision to save money.  The only problem was that Avastin had been developed for the treatment of cancer and not  ophthalmology  whereas the other two drugs had been authorized...